2 June 2023 Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration
Jon S. Heiselman, Brett L. Ecker, Liana Langdon-Embry, Eileen M. O’Reilly, Michael I. Miga, William R. Jarnagin, Richard K. G. Do, Natally Horvat, Alice C. Wei, Jayasree Chakraborty
Author Affiliations +
Abstract

Purpose

Pancreatic ductal adenocarcinoma (PDAC) frequently presents as hypo- or iso-dense masses with poor contrast delineation from surrounding parenchyma, which decreases reproducibility of manual dimensional measurements obtained during conventional radiographic assessment of treatment response. Longitudinal registration between pre- and post-treatment images may produce imaging biomarkers that more reliably quantify treatment response across serial imaging.

Approach

Thirty patients who prospectively underwent a neoadjuvant chemotherapy regimen as part of a clinical trial were retrospectively analyzed in this study. Two image registration methods were applied to quantitatively assess longitudinal changes in tumor volume and tumor burden across the neoadjuvant treatment interval. Longitudinal registration errors of the pancreas were characterized, and registration-based treatment response measures were correlated to overall survival (OS) and recurrence-free survival (RFS) outcomes over 5-year follow-up. Corresponding biomarker assessments via manual tumor segmentation, the standardized response evaluation criteria in solid tumors (RECIST), and pathological examination of post-resection tissue samples were analyzed as clinical comparators.

Results

Average target registration errors were 2.56 ± 2.45 mm for a biomechanical image registration algorithm and 4.15 ± 3.63 mm for a diffeomorphic intensity-based algorithm, corresponding to 1–2 times voxel resolution. Cox proportional hazards analysis showed that registration-derived changes in tumor burden were significant predictors of OS and RFS, while none of the alternative comparators, including manual tumor segmentation, RECIST, or pathological variables were associated with consequential hazard ratios. Additional ROC analysis at 1-, 2-, 3-, and 5-year follow-up revealed that registration-derived changes in tumor burden between pre- and post-treatment imaging were better long-term predictors for OS and RFS than the clinical comparators.

Conclusions

Volumetric changes measured by longitudinal deformable image registration may yield imaging biomarkers to discriminate neoadjuvant treatment response in ill-defined tumors characteristic of PDAC. Registration-based biomarkers may help to overcome visual limits of radiographic evaluation to improve clinical outcome prediction and inform treatment selection.

© 2023 Society of Photo-Optical Instrumentation Engineers (SPIE)
Jon S. Heiselman, Brett L. Ecker, Liana Langdon-Embry, Eileen M. O’Reilly, Michael I. Miga, William R. Jarnagin, Richard K. G. Do, Natally Horvat, Alice C. Wei, and Jayasree Chakraborty "Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration," Journal of Medical Imaging 10(3), 036002 (2 June 2023). https://doi.org/10.1117/1.JMI.10.3.036002
Received: 23 November 2022; Accepted: 15 May 2023; Published: 2 June 2023
Lens.org Logo
CITATIONS
Cited by 1 scholarly publication.
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Image registration

Pancreas

Image segmentation

Deformation

Radiography

Chemotherapy

Back to Top